Federal marijuana rescheduling in 2026 changed the Controlled Substances Act classification for certain marijuana products, but it did not automatically remove marijuana from the Department of Transportation (DOT) drug testing program. DOT-regulated safety-sensitive employees remain subject to marijuana testing under 49 CFR Part 40. A state medical marijuana card does not provide a legitimate medical explanation for a laboratory-confirmed marijuana positive, and state recreational marijuana laws do not create an exception to DOT testing requirements.
What changed with marijuana rescheduling in 2026?
The phrase “marijuana was rescheduled” can be misleading because the 2026 federal action did not simply remove marijuana from the DOT drug testing program.
The important distinction is between Controlled Substances Act scheduling and DOT drug testing requirements. They are related federal frameworks, but changing one does not automatically amend the other.
Key developments include:
- May 2024: The Department of Justice proposed moving marijuana from Schedule I to Schedule III under the Controlled Substances Act.
- December 2025: An Executive Order directed the Department of Justice to expedite the marijuana rescheduling process.
- April 28, 2026: A federal final rule placed FDA-approved drug products containing marijuana and marijuana subject to a state medical marijuana license in Schedule III.
- 2026: The broader federal marijuana rescheduling proceeding continued separately from the specific scheduling action covering certain FDA-approved and state-licensed medical marijuana products.
The key point for DOT-regulated employees is simple: CSA scheduling did not automatically rewrite 49 CFR Part 40. DOT drug testing requirements therefore continue to apply unless DOT changes its own regulations or provides new controlling guidance.
For current federal scheduling developments, see the DEA marijuana rescheduling actions.
Why marijuana rescheduling did not automatically change DOT drug testing
DOT drug testing is governed by 49 CFR Part 40, along with the regulations of the applicable DOT operating agency.
Under 49 CFR 40.85, marijuana metabolites are included among the substances tested under the DOT drug testing program.
That means a change to marijuana’s classification under the Controlled Substances Act does not, by itself, delete marijuana from the DOT testing panel.
For DOT-regulated employees, the practical rule is therefore:
- Marijuana remains part of the DOT drug testing panel.
- DOT-regulated safety-sensitive employees remain subject to marijuana testing.
- State marijuana legalization does not override DOT testing requirements.
- State medical marijuana authorization does not automatically provide a legitimate medical explanation for a DOT marijuana positive.
For a broader explanation of the substances included in DOT testing, see our guide to what drugs are tested for in a DOT drug screen.
Medical marijuana and DOT drug testing
This is one of the most important areas affected by the 2026 rescheduling discussion.
DOT’s May 15, 2026 Part 40 Q&A directly addresses whether an employee can use a state-licensed marijuana product and have an MRO verify a laboratory-confirmed marijuana positive as negative.
The answer is no.
DOT states that there is currently no circumstance in which an MRO can verify a laboratory-confirmed marijuana positive as negative simply because the employee claims the result came from a state-licensed marijuana product.
DOT also explains that state-issued medical marijuana cards, physician recommendations or certifications, and dispensary records or receipts do not satisfy Part 40’s requirements for a legitimate medical explanation.
The reason is important: DOT’s standard for a legitimate medical explanation requires a legally prescribed controlled substance consistent with federal requirements. State-dispensed marijuana is not transformed into an FDA-approved prescription drug simply because a state authorizes its use.
Therefore, a state medical marijuana card does not protect a DOT-regulated employee from the consequences of a confirmed marijuana positive.
See the DOT May 2026 Part 40 Q&A on medical marijuana for the current federal interpretation.
If your question involves a prescription medication rather than marijuana, see our guide to failing a DOT drug test while taking a prescription medication.
Recreational marijuana and DOT rules
State legalization of recreational marijuana does not create an exception to DOT drug testing requirements.
DOT has specifically stated that state recreational marijuana initiatives have no bearing on its regulated drug testing program. Medical Review Officers do not verify a confirmed marijuana positive as negative simply because an employee used marijuana legally under state law.
The same principle applies to off-duty use.
A driver may be off duty when marijuana is used, but that does not remove the employee from DOT testing requirements. A later DOT drug test can detect marijuana metabolites after the effects of marijuana have worn off.
For example, a driver who uses marijuana legally while off duty may still receive a positive result from a later DOT random drug test.
The important distinction is between state-law legality and DOT employment requirements. They are not the same thing.
CBD and hemp-derived cannabinoid products
CBD creates another common source of confusion for DOT-regulated employees.
DOT does not test for CBD itself. However, DOT’s CBD compliance notice warns that CBD products may contain THC and that product labeling may not accurately reflect the amount of THC present.
As a result, using a product marketed as CBD does not guarantee that a DOT marijuana test will remain negative.
- DOT tests for marijuana, not CBD itself.
- Some CBD products may contain THC.
- Product labels may not accurately disclose THC content.
- CBD use is not a legitimate medical explanation for a confirmed DOT marijuana positive.
- A product being sold legally does not make it safe for a DOT-regulated safety-sensitive employee.
The safest approach for employees subject to DOT marijuana testing is to avoid CBD and other cannabinoid products that could expose them to THC.
Employers should also make this risk clear during DOT supervisor and employee training.
Can delta-8 THC cause a DOT marijuana positive?
It can create a testing risk because hemp-derived cannabinoid products may contain THC or other cannabinoids that can expose an employee to substances relevant to marijuana testing.
DOT testing is based on the applicable laboratory testing requirements and confirmed analytes, not on whether a retail product is labeled “hemp,” “CBD,” “delta-8,” or “legal.”
For a DOT-regulated safety-sensitive employee, the product’s marketing claims do not change the consequences of a confirmed DOT marijuana positive.
What happens after a DOT marijuana positive?
A marijuana-positive DOT test can have significant employment and, for CDL drivers, licensing consequences.
- Laboratory testing occurs. The specimen is tested under the applicable DOT and HHS requirements.
- The MRO reviews the result. The Medical Review Officer gives the employee an opportunity to provide a legitimate medical explanation where applicable.
- A verified positive is reported. If the MRO verifies the result as positive, the employer must follow the applicable DOT removal-from-duty requirements.
- The employee is removed from safety-sensitive functions. The employee cannot continue performing DOT-regulated safety-sensitive duties while prohibited from doing so.
- FMCSA drivers may receive a Clearinghouse violation. For CDL drivers subject to FMCSA requirements, a qualifying violation is reported to the FMCSA Drug and Alcohol Clearinghouse.
- The driver can enter prohibited status. Under Clearinghouse II, a driver with prohibited status loses commercial driving privileges until the return-to-duty process is completed.
- The return-to-duty process begins. The employee must complete the applicable Substance Abuse Professional evaluation and treatment/education requirements, receive a negative return-to-duty test, and complete required follow-up testing.
For CDL drivers, Clearinghouse II means that prohibited status can result in the loss or downgrade of commercial driving privileges until the driver completes the required return-to-duty process.
Learn more about what a Clearinghouse violation means for a CDL career, what happens after a failed DOT drug test, and the DOT return-to-duty process.
What DOT-regulated employers should do in 2026
Marijuana rescheduling headlines can create confusion among employees and supervisors. Employers should distinguish between changes to federal drug scheduling and actual changes to DOT requirements.
- Keep DOT and non-DOT requirements separate. DOT testing requirements apply to covered safety-sensitive employees. Non-DOT testing programs may operate under different policies and laws.
- Review your written policy. Make sure the policy accurately describes the employer’s DOT testing requirements and does not promise an exception based on state marijuana laws.
- Train supervisors. Supervisors should know that state marijuana legalization does not automatically change DOT requirements.
- Address CBD and cannabinoid products. Employees should understand that CBD products can contain THC and may create a positive-testing risk.
- Continue required Clearinghouse queries. FMCSA employers must conduct the required pre-employment and annual Clearinghouse queries for covered drivers.
- Monitor DOT guidance. The relevant question is whether DOT changes Part 40 or issues new controlling guidance—not simply whether marijuana’s CSA schedule changes.
Employers operating FMCSA drug and alcohol testing programs should treat marijuana rescheduling as a reason to review employee communications and policies, not as an automatic reason to change DOT testing requirements.
Four common misconceptions about marijuana and DOT testing
| The belief | The reality |
|---|---|
| “Marijuana was rescheduled, so DOT can no longer test for it.” | CSA scheduling and DOT testing requirements are separate regulatory questions. Marijuana remains included in the DOT testing panel under 49 CFR Part 40. |
| “My medical marijuana card protects me.” | No. DOT’s May 2026 guidance says a state medical marijuana card, recommendation, certification, dispensary record, or receipt does not provide a legitimate medical explanation for a laboratory-confirmed marijuana positive. |
| “Marijuana is legal in my state, so off-duty use is allowed under DOT rules.” | State legalization does not create an exception to DOT testing requirements for safety-sensitive employees. |
| “CBD is legal hemp, so it cannot cause a DOT positive.” | CBD products may contain THC, and DOT warns that labels may not accurately disclose THC content. CBD use can therefore create a marijuana-positive testing risk. |
Frequently asked questions
Did marijuana rescheduling change DOT drug testing in 2026?
No. The 2026 federal scheduling action did not automatically remove marijuana from the DOT drug testing program. Marijuana remains included in the DOT testing panel under 49 CFR Part 40, and DOT’s May 2026 guidance continues to address marijuana positives under the existing Part 40 framework.
Is marijuana still on the DOT drug test panel?
Yes. 49 CFR 40.85 includes marijuana metabolites among the substances tested under the DOT drug testing program. A change to the Controlled Substances Act schedule does not automatically amend this DOT regulation.
Does a medical marijuana card protect a CDL driver from a DOT positive?
No. DOT’s May 15, 2026 Part 40 Q&A states that an MRO cannot verify a laboratory-confirmed marijuana positive as negative merely because the employee used a state-licensed marijuana product. State medical marijuana cards, recommendations, certifications, and dispensary records do not satisfy the Part 40 standard for a legitimate medical explanation.
Can a driver use marijuana off duty in a state where it is legal?
State legalization does not create a DOT exception. A safety-sensitive employee remains subject to DOT testing requirements, and marijuana metabolites can remain detectable after the effects of use have ended.
Can CBD cause a positive DOT drug test?
Yes. DOT warns that CBD products may contain THC and that labeling may not accurately disclose THC content. CBD use is also not a legitimate medical explanation for a confirmed DOT marijuana positive.
What happens to a CDL driver who tests positive for marijuana?
A verified DOT marijuana positive can result in removal from safety-sensitive functions and, for an FMCSA-covered CDL driver, a reportable drug and alcohol program violation. The driver may enter prohibited status in the Clearinghouse and must complete the applicable return-to-duty process before resuming prohibited safety-sensitive work.
Will DOT allow marijuana use by safety-sensitive employees because marijuana was rescheduled?
Rescheduling alone does not authorize marijuana use by DOT-regulated safety-sensitive employees. Any change to DOT testing requirements would need to come through the applicable DOT regulatory or guidance process.
Does delta-8 THC show up on a DOT drug test?
Delta-8 and other hemp-derived cannabinoid products can create a marijuana-testing risk, particularly when products contain THC. DOT testing is based on the applicable testing requirements and laboratory results, not on whether a retail product is marketed as legal hemp or delta-8.
Keep your DOT drug testing program current
Marijuana policy is changing at the federal level, but employers and safety-sensitive employees should not assume that every scheduling development changes DOT testing requirements.
New Era Drug Testing provides DOT drug and alcohol testing programs, FMCSA Clearinghouse services, supervisor training, and compliance support, with access to more than 10,000 collection sites nationwide.
See how our DOT-compliant drug and alcohol testing services work, compare enrollment pricing, or contact our compliance team about your DOT testing program. You can also call 800-801-0966.
This article provides general compliance information and is not legal advice. Federal marijuana scheduling and DOT guidance can change. Before making compliance or employment-policy decisions, verify the current requirements with the DOT Office of Drug and Alcohol Policy and Compliance and the applicable DOT operating agency.